Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease

Hypertension Research

Volumn 37, Issue 3, 2014, Pages 246-252

  Yoshitomi, Ryota ^a   Fukui, Akiko ^b   Nakayama, Masaru ^b   Ura, Yoriko ^b   Ikeda, Hirofumi ^b   Oniki, Hideyuki ^b   Tsuchihashi, Takuya ^b   Tsuruya, Kazuhiko ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

cardiac hypertrophy; chronic kidney disease; hyperuricemia; sex difference

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RISK; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGING; CARDIOMEGALY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SEX CHARACTERISTICS; URIC ACID; VENTRICULAR FUNCTION, LEFT;

EID: 84895781568     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.134     Document Type: Article

References (46)

1. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586.
2. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort.The Framingham Heart Study. Ann Intern Med 1989; 110: 101-117.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
6. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354.
7. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997; 12: 724-728.
8. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
9. McMahon LP, Roger SD, Levin ASlimheart Investigators Group. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647.
10. Cioffi G, Tarantini L, Frizzi R, Stefenelli C, Russo TE, Selmi A, Toller C, Furlanello F, de Simone G. Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. J Hypertens 2011; 29: 565-573.
11. Chen SC, Chang JM, Liu WC, Chen YY, Chen LI, Huang JC, Yang TK, Su HM, Chen HC. The ratio of observed to predicted left ventricular mass is independently associated with increased cardiovascular events in patients with chronic kidney disease. Hypertens Res 2012; 35: 832-838.
12. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46: 320-327.
13. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens 2009; 27: 633-641.
14. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992.National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
15. Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988; 224: 549-555.
16. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401-410.
17. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. Am J Epidemiol 1995; 141: 637-644.
18. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078.
19. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
20. Neri L, Rocca Rey LA, Lentine KL, Hinyard LJ, Pinsky B, Xiao H, Dukes J, Schnitzler MA. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58: 398-408.
21. Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, Kuo MC, Chang JM, Hwang SJ, Chen HC. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012; 7: 541-548.
22. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante GP, Del Sette M, Deferrari G, Pontremoli R. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996.
23. Matsumura K, Ohtsubo T, Oniki H, Fujii K, Iida M. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J 2006; 70: 885-888.
24. Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramatsu T, Takefuji S, Hotta Y, Kondo T, Murohara T, Toyoshima H, Tamakoshi K. Uric acid and left ventricular hypertrophy in Japanese men. Circ J 2009; 73: 667-672.
25. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202.
26. Kurata A, Shigematsu Y, Higaki J. Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens Res 2005; 28: 133-139.
27. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239-247.
28. Caliskan Y, Gorgulu N, Yelken B, Akturk F, Yazici H, Turkmen A, Sever MS. Serum uric acid level is associated with cardiac hypertrophy in renal transplant recipients. Clin Tr a n s p l a n t 2011; 25: 368-374.
29. Chen SC, Chang JM, Yeh SM, Su HM, Chen HC. Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease. Am J Hypertens 2013; 26: 243-249.
30. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
31. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
32. Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth 1992; 4: 4-10.
33. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, Laragh JH. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-650.
34. Cuspidi C, Sala C, Negri F, Mancia G, Morganti AItalian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 2012; 26: 343-349.
35. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8608.
36. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
37. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-582.
38. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360.
39. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95: 1247-1252.
40. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998; 83: 345-352.
41. Agabiti-Rosei E, Muiesan ML, Salvetti M. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol 2006; 17: S104-S108.
42. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J 2007; 71: 716-721.
43. Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G, Cebeci BS. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008; 97: 334-340.
44. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257-267.
45. Wingrove CS, Walton C, Stevenson JC. The effect of menopause on serum uric acid levels in non-obese healthy women. Metabolism 1998; 47: 435-438.
46. Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GLONTARGET Investigators. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol 2009; 104: 1484-1489.